Gene Therapies: ‘Trivial’ Changes Will Not Be Rewarded With Orphan Drug Designation And Exclusivity

 
• By Sue Sutter
  
Double helix DNA molecule with modified genes , Correcting mutation by genetic engineering , 3d illustration
US FDA is explaining its view on 'sameness' determinations for gene therapies. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Advanced Technologies